On July 28, Icon PLC rose 10.18% in regular trading, trading at $180.37/share, with turnover of $76.95 million. The surge was driven by the announcement of a multi-year collaboration with Amazon-backed artificial intelligence company Anthropic.

Under the partnership, Icon PLC will integrate Anthropic's Claude AI platform into its clinical trial software to optimize trial site selection, monitor patient enrollment risks, and improve study designs. Financial terms were not disclosed. Notably, this agreement builds upon Icon PLC's earlier selection of Microsoft as a preferred technology partner in June, which included enterprise-wide deployment of Microsoft 365 Copilot and Azure data services to scale its agentic AI platform, Orbis. The dual AI partnerships significantly strengthen the company's positioning in clinical trial automation.

The move comes one day ahead of Icon PLC's quarterly earnings release scheduled for July 29, with consensus estimates projecting revenue of approximately $2.034 billion and adjusted EPS of $2.42. Within the Life Sciences Tools & Services sector, peer IQVIA rose 12.11% and Repligen gained 12.57% on the same session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)